# Targeting Cancer with CAR T Cells Using Small Molecule 'Flags' > This patent describes a method to treat cancer by giving a patient special immune cells (CAR T cells) that are trained to find a specific 'flag' molecule, and then also giving them a drug molecule attached to that same 'flag' in varying amounts or forms. - **Patent:** US 20250171803 - **Original title:** Methods and compositions for car t cell therapy - **Owner:** Purdue Research Foundation - **Status:** Active - **Times cited:** 0 - **Field:** biotech, pharmaceutical, gene_editing, oncology ## What it does This patent details a method for treating cancer by combining CAR T cell therapy with targeted drug delivery. First, a patient receives CAR T cells, which are engineered immune cells designed to recognize a specific 'targeting moiety' (a molecular tag). Then, the patient receives a compound that consists of a 'small molecule ligand' (a drug-like molecule) linked to that same 'targeting moiety' by a 'linker'. The key innovation involves administering this compound in either different doses (Claim 1) or as different versions of the compound (different 'conjugates') (Claims 2 and 3). For example, a patient might receive CAR T cells that recognize a folate-based targeting moiety, and then receive different doses of a folate-linked small molecule drug to direct the CAR T cells to cancer cells. ## What it does NOT cover - CAR T cell therapies that target natural antigens on cancer cells without the use of an externally administered small molecule conjugate. - Small molecule drug delivery systems that do not involve CAR T cells specifically directed to the small molecule's targeting moiety. - Administering the small molecule ligand linked to a targeting moiety in a single, unchanging dose, or as only one type of conjugate. - CAR T cells that are not specifically engineered to recognize the same targeting moiety as the administered small molecule conjugate. - Methods where the small molecule ligand is not linked to a targeting moiety by a linker, as described in the claims. ## The clever bit The novelty lies in the coordinated approach: engineering CAR T cells to recognize a specific molecular 'flag' and then using a small molecule drug attached to that exact 'flag' to guide the CAR T cells to the cancer. The ability to vary the dose or type of this 'flagged' drug allows for fine-tuning the immune response. ## Real-world examples 1. CAR T cell therapies for blood cancers (e.g., Kymriah, Yescarta) 2. Targeted drug delivery systems using small molecules like folate to deliver chemotherapy 3. Experimental cancer treatments combining immunotherapy with targeted agents ## Why it matters CAR T cell therapy is a powerful new way to fight cancer, but it can sometimes cause severe side effects or struggle to find all cancer cells. This patent aims to make CAR T cell therapy more precise and potentially more effective by guiding the immune cells to cancer cells using a specially designed 'flag' molecule. By controlling the doses or types of these 'flag' molecules, doctors might be able to better manage the treatment and its effects. ## Frequently asked questions ### What does Targeting Cancer with CAR T Cells Using Small Molecule 'Flags' cover? This patent describes a method to treat cancer by giving a patient special immune cells (CAR T cells) that are trained to find a specific 'flag' molecule, and then also giving them a drug molecule attached to that same 'flag' in varying amounts or forms. ### Who owns patent US 20250171803? This patent is owned by Purdue Research Foundation. ### When does this patent expire? This patent is expected to expire on October 14, 2044, when the invention enters the public domain. ### What problem does this patent solve? CAR T cell therapy is a powerful new way to fight cancer, but it can sometimes cause severe side effects or struggle to find all cancer cells. This patent aims to make CAR T cell therapy more precise and potentially more effective by guiding the immune cells to cancer cells using a specially designed 'flag' molecule. By controlling the doses or types of these 'flag' molecules, doctors might be able to better manage the treatment and its effects. ### What does this patent NOT cover? CAR T cell therapies that target natural antigens on cancer cells without the use of an externally administered small molecule conjugate. **Full plain-English explainer:** https://patentbrief.org/patent/us/20250171803/methods-and-compositions-for-car-t-cell-therapy **Original patent:** https://patents.google.com/patent/US20250171803 --- _Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._ ## Related patents Semantically similar inventions in the PatentBrief corpus: - [Targeting Cancer with CAR T Cells Using a Chemical Tag](https://patentbrief.org/patent/us/20240165159/compositions-and-methods-for-car-t-cell-therapy) — This patent describes a method to treat cancer by giving a patient special immune cells (CAR T cells) that recognize a chemical tag, which is attached to a small drug molecule, along with a separate folate compound. - [How Special Molecules Boost Cancer-Fighting CAR-T Cells](https://patentbrief.org/patent/us/20240082373/compositions-for-chimeric-antigen-receptor-t-cell-therapy-and-uses-thereof) — This patent describes special molecules made of a CAR-T cell activator attached to a fat-like part, designed to make cancer-fighting CAR-T cells grow and work better inside a patient. - [How Genetically Modified T-Cells Fight CD19 Cancers](https://patentbrief.org/patent/us/9481728/compositions-and-methods-for-treatment-of-cancer) — This patent describes how to create and use genetically modified human T cells that target and kill cancer cells expressing the CD19 protein, offering a new way to treat blood cancers. - [How Genetically Modified T-Cells Attack Cancer](https://patentbrief.org/patent/us/9328156/use-of-chimeric-antigen-receptor-modified-t-cells-to-treat-cancer) — This patent describes how human T cells are genetically engineered to express a special receptor (CAR) that specifically targets and kills cancer cells, particularly those with the CD19 marker, offering a new way to treat cancer. - [Treating a Specific Lymphoma with Modified T Cells](https://patentbrief.org/patent/us/12600775/chimeric-antigen-receptor-t-cell-therapy) — This patent describes a method to treat a difficult-to-treat type of lymphoma by taking a patient's own immune cells, modifying them to recognize and attack cancer, and then giving them back to the patient.